On August 18, 2026, Genprex, Inc. announced a development and manufacturing agreement with a leading U.S.-based Contract Development and Manufacturing Organization to initiate the manufacturing scale-up of its diabetes gene therapy program. This partnership transitions the therapeutic candidate from research-grade production to clinical and commercial-ready output using cGMP-compliant facilities. The CDMO will supply drug product for IND-enabling preclinical studies and future trials, focusing on process optimization, scale-up via capacity bioreactors, analytical qualification, and GMP compliance. Genprex is a biotechnology company developing gene therapies for Type 1 and Type 2 diabetes.

On August 3, 2026, Genprex announced a collaboration with Roche Diagnostics to validate TROP2 as a biomarker for patient selection in non-small cell lung cancer clinical trials. The partnership leverages Roche's FDA Breakthrough Device Designation for an AI-driven companion diagnostic using the same TROP2 antibody employed by Genprex. Preclinical and clinical data suggest that high TROP2 and low PTEN expression levels correlate with improved progression-free survival. Genprex expects to complete validation studies by late 2026, aiming to accelerate patient recruitment and refine precision medicine strategies for NSCLC. Genprex is a biopharmaceutical company focused on developing targeted therapies for cancer and diabetes.

On July 29, 2026, the Nasdaq Hearings Panel granted Genprex an exception to maintain its listing on The Nasdaq Capital Market despite failing to meet the $1.00 Minimum Bid Price requirement. The company must demonstrate compliance by July 29, 2026, and maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026. Genprex implemented a one-for-twenty-two (1:22) reverse stock split effective July 16, 2026, to address the deficiency. Failure to comply with these terms may result in delisting, which could negatively impact liquidity and capital access. Genprex is a clinical-stage biopharmaceutical company developing targeted therapies for cancer.

Genprex, Inc. announced a one-for-twenty-two (1:22) reverse stock split of its common stock, effective July 16, 2026, to help regain compliance with Nasdaq's $1.00 minimum bid price requirement. The company also provided updates on its Acclaim-1 and Acclaim-3 clinical trials for its gene therapy programs. Genprex, Inc. is a biotechnology company focused on oncology and diabetes gene therapy.

Genprex, Inc. announced that the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 or PD-L1 antibodies for treating lung cancer. This patent expands on existing patents granted in the U.S., Japan, Mexico, Russia, Chile, China, Singapore, Europe, and other regions. Genprex, Inc. is a biotechnology company developing gene therapy products for oncology and diabetes.

At its 2026 Annual Meeting on June 18, 2026, Genprex, Inc. stockholders approved an amended and restated 2018 Equity Incentive Plan, increasing authorized common stock issuance by 1,850,000 shares. Stockholders also approved an amendment to the Certificate of Incorporation granting the Board of Directors sole discretion to implement a reverse stock split between 1:5 and 1:50 at any time before December 31, 2027. Other approved items included the election of directors Jose Antonio Moreno Toscano and Ryan M. Confer, and the ratification of WithumSmith+Brown, PC as the independent auditor. Genprex is a biotechnology company that develops therapeutic products.